, Crohn's Disease and Ulcerative Colitis-From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach, Baumgart DC eS, vol.1461409977, 2012.
, Comparative study of ASCA
Diagnostic precision of antiSaccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease, Am J Gastroenterol, vol.101, issue.10, pp.2410-2432, 2006. ,
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease, Aliment Pharmacol Ther, vol.34, issue.2, pp.125-170, 2011. ,
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease ,
, Montreal World Congress of Gastroenterology, Can J Gastroenterol, vol.19, pp.5-36, 2005.
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012. ,
Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data, Inflamm Bowel Dis, vol.12, issue.3, pp.218-244, 2006.,
URL : https://hal.archives-ouvertes.fr/hal-00466309
The global burden of IBD: from 2015 to 2025, Nat Rev Gastroenterol Hepatol, vol.12, issue.12, pp.720-727, 2015. ,
The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases, JAMA Pediatr, vol.171, issue.10, pp.999-1005, 2017. ,
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci, Nat Genet, vol.42, issue.12, pp.1118-1143, 2010. ,
Defects in Mucosal Immunity Leading to Crohn's Disease, Immunological Reviews, vol.206, pp.277-95, 2005. ,
Defects in Mucosal Immunity Leading to Ulcerative Colitis, Immunological Reviews, vol.206, pp.296-305, 2005. ,
Positioning biologic therapy for Crohn's disease and ulcerative colitis, Curr Gastroenterol Rep, vol.9, pp.521-527, 2007. ,
Sachar, and Practice Parameters Committee of the ,
Ulcerative Colitis Practice Guidelines in Adults ,
, American College Of Gastroenterology, Practice Parameters Committee, The American Journal of Gastroenterology, vol.105, issue.3, pp.501-523, 2010.
Efficacy and Safety of Adalimumab in Ulcerative ,
, Colitis Refractory to Conventional Therapy in Routine Clinical Practice, Journal of Crohn's & Colitis, vol.10, issue.1, pp.26-30, 2016.
3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management, Journal of Crohn's & Colitis, vol.11, issue.1, pp.3-25, 2017. ,
Predictors of Crohn's disease, Gastroenterology, vol.130, issue.3, pp.650-656, 2006. ,
Treatment of Ulcerative Colitis with a ,
, Humanized Antibody to the alpha4beta7 Integrin, The New England Journal of Medicine, vol.352, issue.24, pp.2499-2507, 2005.
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha4beta7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases, The Journal of Pharmacology and Experimental Therapeutics, vol.330, issue.3, pp.864-75, 2009. ,
Vedolizumab as induction and maintenance therapy for ulcerative colitis, N. Engl. J. Med, vol.369, pp.699-721, 2013. ,
Effectiveness and Safety of,
URL : https://hal.archives-ouvertes.fr/hal-01278611
, Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, vol.14, issue.11, pp.1593-1601, 2016.
, Mechanisms of Action of Infliximab in Inflammatory Bowel Disease
, Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol.40, issue.2, pp.225-228, 2008.
Postinduction Serum Infliximab Trough Level and Decrease of C-Reactive Protein Level Are Associated with Durable Sustained Response to Infliximab: A Retrospective Analysis of the ACCENT I Trial, Gut, 2014. ,
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet, vol.371, pp.660-667, 2008. ,
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of Mucosal Healing on the Course of Inflammatory Bowel Disease, Journal of Crohn's & Colitis, vol.5, issue.5, pp.477-83, 2011. ,
PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium, Inflammatory Bowel Diseases, vol.23, 2017. ,
Effect of Vedolizumab (Anti-?4?7-Integrin) ,
, Therapy on Histological Healing and Mucosal Gene Expression in Patients with UC, Gut, 2016.
Vedolizumab Induces Long Term Mucosal Healing in Patients with Crohn's Disease and Ulcerative Colitis, Journal of Crohn's & Colitis, 2017. ,
Association of Trough Serum Infliximab to Clinical Outcome after Scheduled Maintenance Treatment for Crohn's Disease, Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, vol.4, issue.10, pp.1248-54, 2006. ,
Association between Serum Concentration of Infliximab and Efficacy in Adult Patients with Ulcerative Colitis, Gastroenterology, vol.147, issue.6, pp.1296-1307, 2014. ,
Infliximab Trough Levels May Predict Sustained Response to Infliximab in Patients with Crohn's Disease, Journal of Crohn's & Colitis, vol.7, issue.9, pp.736-779, 2013. ,
The Relationship between Infliximab Concentrations, Antibodies to Infliximab and Disease Activity in Crohn's Disease, Gut, vol.64, issue.10, pp.1539-1584, 2014. ,
Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease, Journal of Crohn's & Colitis, vol.10, issue.5, pp.619-644, 2016. ,
Relationship between Serum Infliximab Trough Levels and Endoscopic Activities in Patients with Crohn's Disease under Scheduled Maintenance Treatment, Journal of Gastroenterology, vol.49, issue.4, pp.674-82, 2014. ,
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study, Inflammatory Bowel Diseases, vol.19, issue.12, pp.2568-76, 2013. ,
Optimizing Anti-TNF-? Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, vol.14, issue.4, 2016. ,
Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies, Journal of Crohn's & Colitis, vol.11, issue.1, pp.35-46, 2017. ,
Population PharmacokineticsPharmacodynamics of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease, Alimentary Pharmacology & Therapeutics, vol.42, issue.2, pp.188-202, 2015. ,
Exposure-Efficacy Relationships for ,
, Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease, Journal of Crohn's & Colitis, vol.11, issue.8, pp.921-950, 2017.
Association Between Low Trough Levels of,
URL : https://hal.archives-ouvertes.fr/hal-01908856
, Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months, Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 2016.
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study, Inflammatory Bowel Diseases, vol.23, issue.11, pp.2048-53, 2017.,
URL : https://hal.archives-ouvertes.fr/hal-01953658
Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target, Am J Gastroenterol, vol.110, pp.1324-1362, 2015.,
URL : https://hal.archives-ouvertes.fr/hal-01191653
Crohn's disease, Lancet, vol.389, pp.1741-55, 2017. ,
Ulcerative colitis, Lancet, vol.389, pp.1756-70, 2017. ,
Results from the 2nd scientific workshop of the ECCO: Impact of mucosal healing on the course of inflammatory bowel disease, J Crohns Colitis, vol.5, pp.477-83, 2011. ,
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment, J Gastroenterol, vol.49, pp.674-82, 2014. ,
Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study, Inflamm Bowel Dis, vol.19, pp.2568-76, 2013. ,
Optimizing anti-TNF-? therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases, Clin Gastroenterol Hepatol Association, vol.14, pp.550-557, 2016. ,
, FDA Approved Drug Products, 2017.
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study, Aliment Pharmacol Ther, vol.48, issue.3, pp.310-321, 2017.,
URL : https://hal.archives-ouvertes.fr/hal-01639670
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease, Aliment Pharmacol Ther, vol.46, issue.1, pp.3-15, 2017. ,
Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis ,
, Aliment Pharmacol Ther, vol.45, issue.1, pp.3-13, 2017.
Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn's disease, J Crohns Colitis, 2017. ,
Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months, Clin Gastroenterol Hepatol, 2016.,
URL : https://hal.archives-ouvertes.fr/hal-01908856
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials, Aliment Pharmacol Ther, vol.45, issue.10, pp.1291-1302, 2017. ,
Vedolizumab induces long term mucosal healing in patients with Crohn's disease and ulcerative colitis, J Crohns Colitis, 2017. ,
Mucosal healing with vedolizumab in ulcerative colitis and Crohn's disease: outcomes from the VICTORY consortium, Inflamm Bowel Dis, vol.23, 2017. ,
, The R Project for Statistical Computing. Accessed, 2017.
Systematic review and metaanalysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease, J Crohns Colitis, vol.10, pp.619-644, 2016. ,
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease, Gut, vol.64, pp.1539-1584, 2015. ,
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial, Aliment Pharmacol Ther, vol.45, issue.2, pp.264-275, 2017. ,
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment, J Gastroenterol, vol.49, pp.674-682, 2014. ,
Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study, Inflamm Bowel Dis,
URL : https://hal.archives-ouvertes.fr/hal-01953658